img

Global Pulmonary Hypertension Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pulmonary Hypertension Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Pulmonary Hypertension Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pulmonary Hypertension Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinic and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pulmonary Hypertension Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pulmonary Hypertension Drug key manufacturers include Sanofi, Vectura Group plc, Bayer AG, Ikaria Inc., Proreo Pharma AG, Vicore Pharma AB, Biolab Sanus Farmaceutica Ltda. and Hanmi Pharmaceuticals, Co. Ltd., etc. Sanofi, Vectura Group plc, Bayer AG are top 3 players and held % sales share in total in 2022.
Pulmonary Hypertension Drug can be divided into IK-3001, Sildenafil Citrate IMD, IK-7002 and Riociguat, etc. IK-3001 is the mainstream product in the market, accounting for % sales share globally in 2022.
Pulmonary Hypertension Drug is widely used in various fields, such as Clinic, Hospital and Others,, etc. Clinic provides greatest supports to the Pulmonary Hypertension Drug industry development. In 2022, global % sales of Pulmonary Hypertension Drug went into Clinic filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pulmonary Hypertension Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Sanofi
Vectura Group plc
Bayer AG
Ikaria Inc.
Proreo Pharma AG
Vicore Pharma AB
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals, Co. Ltd.
Segment by Type
IK-3001
Sildenafil Citrate IMD
IK-7002
Riociguat
SAR-407899
Others

Segment by Application


Clinic
Hospital
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pulmonary Hypertension Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pulmonary Hypertension Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pulmonary Hypertension Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pulmonary Hypertension Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pulmonary Hypertension Drug introduction, etc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pulmonary Hypertension Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Pulmonary Hypertension Drug Market Overview
1.1 Pulmonary Hypertension Drug Product Overview
1.2 Pulmonary Hypertension Drug Market Segment by Type
1.2.1 IK-3001
1.2.2 Sildenafil Citrate IMD
1.2.3 IK-7002
1.2.4 Riociguat
1.2.5 SAR-407899
1.2.6 Others
1.3 Global Pulmonary Hypertension Drug Market Size by Type
1.3.1 Global Pulmonary Hypertension Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Pulmonary Hypertension Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Pulmonary Hypertension Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pulmonary Hypertension Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Pulmonary Hypertension Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Pulmonary Hypertension Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Pulmonary Hypertension Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Pulmonary Hypertension Drug Sales Breakdown by Type (2018-2024)
2 Global Pulmonary Hypertension Drug Market Competition by Company
2.1 Global Top Players by Pulmonary Hypertension Drug Sales (2018-2024)
2.2 Global Top Players by Pulmonary Hypertension Drug Revenue (2018-2024)
2.3 Global Top Players by Pulmonary Hypertension Drug Price (2018-2024)
2.4 Global Top Manufacturers Pulmonary Hypertension Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pulmonary Hypertension Drug Market Competitive Situation and Trends
2.5.1 Pulmonary Hypertension Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Pulmonary Hypertension Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Hypertension Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Pulmonary Hypertension Drug Market
2.8 Key Manufacturers Pulmonary Hypertension Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pulmonary Hypertension Drug Status and Outlook by Region
3.1 Global Pulmonary Hypertension Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Pulmonary Hypertension Drug Historic Market Size by Region
3.2.1 Global Pulmonary Hypertension Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Pulmonary Hypertension Drug Sales in Value by Region (2018-2024)
3.2.3 Global Pulmonary Hypertension Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Pulmonary Hypertension Drug Forecasted Market Size by Region
3.3.1 Global Pulmonary Hypertension Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Pulmonary Hypertension Drug Sales in Value by Region (2024-2034)
3.3.3 Global Pulmonary Hypertension Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Pulmonary Hypertension Drug by Application
4.1 Pulmonary Hypertension Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Pulmonary Hypertension Drug Market Size by Application
4.2.1 Global Pulmonary Hypertension Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Pulmonary Hypertension Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Pulmonary Hypertension Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Pulmonary Hypertension Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Pulmonary Hypertension Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Pulmonary Hypertension Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Pulmonary Hypertension Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Pulmonary Hypertension Drug Sales Breakdown by Application (2018-2024)
5 North America Pulmonary Hypertension Drug by Country
5.1 North America Pulmonary Hypertension Drug Historic Market Size by Country
5.1.1 North America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Pulmonary Hypertension Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Pulmonary Hypertension Drug Sales in Value by Country (2018-2024)
5.2 North America Pulmonary Hypertension Drug Forecasted Market Size by Country
5.2.1 North America Pulmonary Hypertension Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Pulmonary Hypertension Drug Sales in Value by Country (2024-2034)
6 Europe Pulmonary Hypertension Drug by Country
6.1 Europe Pulmonary Hypertension Drug Historic Market Size by Country
6.1.1 Europe Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Pulmonary Hypertension Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Pulmonary Hypertension Drug Sales in Value by Country (2018-2024)
6.2 Europe Pulmonary Hypertension Drug Forecasted Market Size by Country
6.2.1 Europe Pulmonary Hypertension Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Pulmonary Hypertension Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Pulmonary Hypertension Drug by Region
7.1 Asia-Pacific Pulmonary Hypertension Drug Historic Market Size by Region
7.1.1 Asia-Pacific Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Pulmonary Hypertension Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Pulmonary Hypertension Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Pulmonary Hypertension Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Pulmonary Hypertension Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Pulmonary Hypertension Drug Sales in Value by Region (2024-2034)
8 Latin America Pulmonary Hypertension Drug by Country
8.1 Latin America Pulmonary Hypertension Drug Historic Market Size by Country
8.1.1 Latin America Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Pulmonary Hypertension Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Pulmonary Hypertension Drug Sales in Value by Country (2018-2024)
8.2 Latin America Pulmonary Hypertension Drug Forecasted Market Size by Country
8.2.1 Latin America Pulmonary Hypertension Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Pulmonary Hypertension Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Pulmonary Hypertension Drug by Country
9.1 Middle East and Africa Pulmonary Hypertension Drug Historic Market Size by Country
9.1.1 Middle East and Africa Pulmonary Hypertension Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Pulmonary Hypertension Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Pulmonary Hypertension Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Pulmonary Hypertension Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Pulmonary Hypertension Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Pulmonary Hypertension Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Sanofi
10.1.1 Sanofi Company Information
10.1.2 Sanofi Introduction and Business Overview
10.1.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Sanofi Pulmonary Hypertension Drug Products Offered
10.1.5 Sanofi Recent Development
10.2 Vectura Group plc
10.2.1 Vectura Group plc Company Information
10.2.2 Vectura Group plc Introduction and Business Overview
10.2.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Vectura Group plc Pulmonary Hypertension Drug Products Offered
10.2.5 Vectura Group plc Recent Development
10.3 Bayer AG
10.3.1 Bayer AG Company Information
10.3.2 Bayer AG Introduction and Business Overview
10.3.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Bayer AG Pulmonary Hypertension Drug Products Offered
10.3.5 Bayer AG Recent Development
10.4 Ikaria Inc.
10.4.1 Ikaria Inc. Company Information
10.4.2 Ikaria Inc. Introduction and Business Overview
10.4.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Ikaria Inc. Pulmonary Hypertension Drug Products Offered
10.4.5 Ikaria Inc. Recent Development
10.5 Proreo Pharma AG
10.5.1 Proreo Pharma AG Company Information
10.5.2 Proreo Pharma AG Introduction and Business Overview
10.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Products Offered
10.5.5 Proreo Pharma AG Recent Development
10.6 Vicore Pharma AB
10.6.1 Vicore Pharma AB Company Information
10.6.2 Vicore Pharma AB Introduction and Business Overview
10.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Products Offered
10.6.5 Vicore Pharma AB Recent Development
10.7 Biolab Sanus Farmaceutica Ltda.
10.7.1 Biolab Sanus Farmaceutica Ltda. Company Information
10.7.2 Biolab Sanus Farmaceutica Ltda. Introduction and Business Overview
10.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Products Offered
10.7.5 Biolab Sanus Farmaceutica Ltda. Recent Development
10.8 Hanmi Pharmaceuticals, Co. Ltd.
10.8.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
10.8.2 Hanmi Pharmaceuticals, Co. Ltd. Introduction and Business Overview
10.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Products Offered
10.8.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pulmonary Hypertension Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pulmonary Hypertension Drug Industrial Chain Analysis
11.4 Pulmonary Hypertension Drug Market Dynamics
11.4.1 Pulmonary Hypertension Drug Industry Trends
11.4.2 Pulmonary Hypertension Drug Market Drivers
11.4.3 Pulmonary Hypertension Drug Market Challenges
11.4.4 Pulmonary Hypertension Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pulmonary Hypertension Drug Distributors
12.3 Pulmonary Hypertension Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of IK-3001
Table 2. Major Company of Sildenafil Citrate IMD
Table 3. Major Company of IK-7002
Table 4. Major Company of Riociguat
Table 5. Major Company of SAR-407899
Table 6. Major Company of Others
Table 7. Global Pulmonary Hypertension Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Pulmonary Hypertension Drug Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Pulmonary Hypertension Drug Sales by Type (2018-2024) & (US& Million)
Table 11. Global Pulmonary Hypertension Drug Market Share in Value by Type (2018-2024)
Table 12. Global Pulmonary Hypertension Drug Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Pulmonary Hypertension Drug Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Pulmonary Hypertension Drug Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Pulmonary Hypertension Drug Sales Market Share in Value by Type (2024-2034)
Table 17. Global Pulmonary Hypertension Drug Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Pulmonary Hypertension Drug Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Pulmonary Hypertension Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Pulmonary Hypertension Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Pulmonary Hypertension Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Pulmonary Hypertension Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Pulmonary Hypertension Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Pulmonary Hypertension Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Pulmonary Hypertension Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Pulmonary Hypertension Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Pulmonary Hypertension Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Pulmonary Hypertension Drug Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Pulmonary Hypertension Drug Sales Share by Company (2018-2024)
Table 30. Global Pulmonary Hypertension Drug Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Pulmonary Hypertension Drug Revenue Share by Company (2018-2024)
Table 32. Global Market Pulmonary Hypertension Drug Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Pulmonary Hypertension Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Pulmonary Hypertension Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Hypertension Drug as of 2022)
Table 36. Date of Key Manufacturers Enter into Pulmonary Hypertension Drug Market
Table 37. Key Manufacturers Pulmonary Hypertension Drug Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Pulmonary Hypertension Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Pulmonary Hypertension Drug Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Pulmonary Hypertension Drug Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Pulmonary Hypertension Drug Sales Market Share in Value by Region (2018-2024)
Table 44. Global Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Pulmonary Hypertension Drug Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Pulmonary Hypertension Drug Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Pulmonary Hypertension Drug Sales Market Share in Value by Region (2024-2034)
Table 49. Global Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Pulmonary Hypertension Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Pulmonary Hypertension Drug Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Pulmonary Hypertension Drug Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Pulmonary Hypertension Drug Sales Market Share in Value by Application (2018-2024)
Table 55. Global Pulmonary Hypertension Drug Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Pulmonary Hypertension Drug Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Pulmonary Hypertension Drug Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Pulmonary Hypertension Drug Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Pulmonary Hypertension Drug Sales Market Share in Value by Application (2024-2034)
Table 60. Global Pulmonary Hypertension Drug Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Pulmonary Hypertension Drug Sales by Application (2018-2024) (K Pcs)
Table 62. North America Pulmonary Hypertension Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Pulmonary Hypertension Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Pulmonary Hypertension Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Pulmonary Hypertension Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Pulmonary Hypertension Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Pulmonary Hypertension Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Pulmonary Hypertension Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Pulmonary Hypertension Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Pulmonary Hypertension Drug Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Pulmonary Hypertension Drug Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Pulmonary Hypertension Drug Sales Market Share in Value by Country (2018-2024)
Table 75. North America Pulmonary Hypertension Drug Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Pulmonary Hypertension Drug Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Pulmonary Hypertension Drug Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Pulmonary Hypertension Drug Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Pulmonary Hypertension Drug Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Pulmonary Hypertension Drug Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Pulmonary Hypertension Drug Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Pulmonary Hypertension Drug Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Pulmonary Hypertension Drug Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Pulmonary Hypertension Drug Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Pulmonary Hypertension Drug Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Pulmonary Hypertension Drug Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Pulmonary Hypertension Drug Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Pulmonary Hypertension Drug Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Pulmonary Hypertension Drug Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Pulmonary Hypertension Drug Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Pulmonary Hypertension Drug Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Pulmonary Hypertension Drug Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Pulmonary Hypertension Drug Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Value by Country (2024-2034)
Table 111. Sanofi Company Information
Table 112. Sanofi Introduction and Business Overview
Table 113. Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. Sanofi Pulmonary Hypertension Drug Product
Table 115. Sanofi Recent Development
Table 116. Vectura Group plc Company Information
Table 117. Vectura Group plc Introduction and Business Overview
Table 118. Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. Vectura Group plc Pulmonary Hypertension Drug Product
Table 120. Vectura Group plc Recent Development
Table 121. Bayer AG Company Information
Table 122. Bayer AG Introduction and Business Overview
Table 123. Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Bayer AG Pulmonary Hypertension Drug Product
Table 125. Bayer AG Recent Development
Table 126. Ikaria Inc. Company Information
Table 127. Ikaria Inc. Introduction and Business Overview
Table 128. Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. Ikaria Inc. Pulmonary Hypertension Drug Product
Table 130. Ikaria Inc. Recent Development
Table 131. Proreo Pharma AG Company Information
Table 132. Proreo Pharma AG Introduction and Business Overview
Table 133. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. Proreo Pharma AG Pulmonary Hypertension Drug Product
Table 135. Proreo Pharma AG Recent Development
Table 136. Vicore Pharma AB Company Information
Table 137. Vicore Pharma AB Introduction and Business Overview
Table 138. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 139. Vicore Pharma AB Pulmonary Hypertension Drug Product
Table 140. Vicore Pharma AB Recent Development
Table 141. Biolab Sanus Farmaceutica Ltda. Company Information
Table 142. Biolab Sanus Farmaceutica Ltda. Introduction and Business Overview
Table 143. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 144. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product
Table 145. Biolab Sanus Farmaceutica Ltda. Recent Development
Table 146. Hanmi Pharmaceuticals, Co. Ltd. Company Information
Table 147. Hanmi Pharmaceuticals, Co. Ltd. Introduction and Business Overview
Table 148. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 149. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product
Table 150. Hanmi Pharmaceuticals, Co. Ltd. Recent Development
Table 151. Key Raw Materials Lists
Table 152. Raw Materials Key Suppliers Lists
Table 153. Pulmonary Hypertension Drug Market Trends
Table 154. Pulmonary Hypertension Drug Market Drivers
Table 155. Pulmonary Hypertension Drug Market Challenges
Table 156. Pulmonary Hypertension Drug Market Restraints
Table 157. Pulmonary Hypertension Drug Distributors List
Table 158. Pulmonary Hypertension Drug Downstream Customers
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Hypertension Drug Product Picture
Figure 2. Global Pulmonary Hypertension Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pulmonary Hypertension Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Pulmonary Hypertension Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of IK-3001
Figure 6. Global IK-3001 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Sildenafil Citrate IMD
Figure 8. Global Sildenafil Citrate IMD Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of IK-7002
Figure 10. Global IK-7002 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Riociguat
Figure 12. Global Riociguat Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of SAR-407899
Figure 14. Global SAR-407899 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Others
Figure 16. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Pulmonary Hypertension Drug Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Pulmonary Hypertension Drug Sales Market Share by Type in 2022 & 2034
Figure 19. North America Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2022
Figure 20. North America Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2022
Figure 21. Europe Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2022
Figure 22. Europe Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2022
Figure 25. Latin America Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Pulmonary Hypertension Drug Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Pulmonary Hypertension Drug Revenue in 2022
Figure 31. Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Clinic
Figure 33. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Hospital
Figure 35. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Pulmonary Hypertension Drug Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Pulmonary Hypertension Drug Sales Market Share by Application in 2022 & 2034
Figure 40. North America Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2022
Figure 41. North America Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2022
Figure 42. Europe Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2022
Figure 43. Europe Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2022
Figure 46. Latin America Pulmonary Hypertension Drug Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Pulmonary Hypertension Drug Manufacturing Cost Structure
Figure 51. Pulmonary Hypertension Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries